Stent

1. A method of manufacturing a stent using a three dimensional (3D) printer, the method comprising:

(i) installing a computer-readable design of a stent on a computer, which is operably connected to a 3D printer comprising a nozzle and a stage; and

(ii) instructing the 3D printer to print the design of the stent, such that

a) non-metallic ink comprising a thermoplastic polymer is heated to a temperature at least 1° C. above the melting point/glass transition temperature of the ink, and is then expelled from the nozzle onto the stage to form a first layer of printed material, and consequently depositing layer upon layer of printed ink to thereby form the stent, or

(b) a support material is expelled from the nozzle onto the stage to form a first layer, and then non-metallic ink comprising a thermoplastic polymer is heated to a temperature at least 1° C. above the melting point/glass transition temperature of the ink, and is then expelled from the nozzle onto the first layer to form a second layer, and the support material and the non-metallic ink are then expelled alternately to form alternate layers, and thereby form the stent.

2. A method according to claim 1 , wherein the diameter of the printer nozzle outlet aperture is at least 10 μm, 25 μm, 50 μm, 75 μm, 85 μm or 100 μm, or wherein the diameter of the printer nozzle outlet aperture is less than 600 μm, 500 μm, 450 μm, 400 μm, 350 μm or 300 μm.

3. A method according to claim 1 , wherein the printing resolution of the 3D printer is at least 6 μm, 8 μm, 10 μm, 12 μm, 14 μm or 16 μm.

4. A method according to claim 1 , wherein the method comprises heating the ink to a temperature that is 10° C., 5° C., or 2° C. above the melting point/glass transition temperature of the ink before it is dispensed by the printer nozzle.

5. A method according to claim 1 , wherein the ink is dispensed in a semi-liquid state or in the form of droplets.

6. A method according to claim 1 , wherein the method comprises depositing the ink in or on the surface of a stent support structure.

7. A method according to claim 5 , wherein the method comprises passing a milling head over the printed layer of the stent to ensure that it is of uniform thickness.

8. A method according to claim 1 , wherein the computer-readable design is a computer-aided design (CAD).

9. A method according to claim 1 , wherein the method comprises applying a therapeutic agent to the surface of the stent by spraying or by printing.

10. A method according to claim 1 , wherein the method comprises contacting the ink with a therapeutic agent or drug to form a mixture which is then expelled through the nozzle to print the stent.

11. A method according to claim 10 , wherein the method comprises heating the mixture of the ink and the therapeutic agent, such that hot melt is extruded from the printer nozzle and used to create the stent.

12. A stent obtained or obtainable by the method according to claim 1 , wherein the ink has a tensile strength above 10 MPa.

13. A stent according to claim 12 , wherein the stent is a bioabsorbable stent or a drug-eluting stent comprising a therapeutically effective amount of a therapeutic agent.

14. A stent according to claim 13 , wherein the therapeutic agent is hydrophobic or hydrophilic or wherein the therapeutic agent is distributed in solidified ink of the stent.

15. A stent according to claim 12 , wherein the ink has a tensile strength above 15 megapascal (MPa) or 20 MPa, or a tensile strength below 500 MPa, 375 MPa or 250 MPa.

16. A stent according to claim 12 , wherein the thickness of struts of the stent is at least 80 μm, 100 μm or 150 μm, or at most 650 μm, 600 μm or 550 μm.

17. A stent according to claim 12 , wherein the vascular coverage of the stent is 5 to 60%, 10 to 50% or 10 to 40%.

18. A method of treating a vascular disease in a subject in need of such treatment, the method comprising fitting the stent according to claim 12 into a blood vessel of the subject.

19. A method according to claim 18 wherein the vascular disease is stenosis, restenosis, thrombosis, hypertension, hemophilia, angioedema, hyperlipidemia, vasculitis, peripheral vascular disease, an aneurysm or an intracranial aneurysm.

20. A method according to claim 1 , wherein the thermoplastic polymer is selected from the group consisting of: poly-lactic acid (PLA), poly-caprolcatone (PCL), poly-glycolic acid (PGA), poly(D,L-lactide-co-glycolide) (PLGA), poly (D,L-lactide) (PLLA), polymethyl methacrylate (PMMA), chitosan, polyurethane, hydroxypropylmethylcellulose (HPMC), gelatine, and combinations thereof.

21. A method according to claim 1 , wherein the stage comprises a substantially flat surface.